When does continued treatment with the Esteve Pharmaceuticals (formerly Intrapharm Laboratories) co-amoxiclav 1000/200 mg injection/infusion product require review?

Treatment with the Esteve Pharmaceuticals (formerly Intrapharm Laboratories) co-amoxiclav 1000/200 mg injection/infusion product must be reviewed before extending beyond 14 days, with duration determined by patient response, even when infections such as osteomyelitis require longer treatment.